Nanjing Vazyme Biotech Co.,Ltd Stock

Equities

688105

CNE100004ZK3

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
27.96 CNY +1.05% Intraday chart for Nanjing Vazyme Biotech Co.,Ltd +5.43% -12.68%

Financials

Sales 2024 * 1.6B 221M 303M Sales 2025 * 2.01B 278M 380M Capitalization 11.18B 1.54B 2.11B
Net income 2024 * 319M 44.06M 60.3M Net income 2025 * 467M 64.5M 88.28M EV / Sales 2024 * 6.99 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 5.56 x
P/E ratio 2024 *
38.7 x
P/E ratio 2025 *
26.2 x
Employees 2,904
Yield 2024 *
1.07%
Yield 2025 *
1.07%
Free-Float 20.96%
More Fundamentals * Assessed data
Dynamic Chart
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14% MT
China stocks rise after new guidelines; HK shares drop RE
Nanjing Vazyme Biotech Swings to Loss in 2023 MT
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 160 million worth of its shares. CI
Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan. CI
Tranche Update on Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback Plan announced on August 22, 2023. CI
Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback announced on August 22, 2023, has closed with 618,077 shares, representing 0.15% for CNY 20.01 million. CI
Certain A Shares of Nanjing Vazyme Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-NOV-2023. CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Vazyme Biotech Co.,Ltd(XSSC:688105) added to S&P Global BMI Index CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing Vazyme Biotech Plans Up to 30 Million Yuan Share Buyback MT
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares. CI
More news
1 day+1.05%
1 week+5.43%
1 month+19.64%
3 months+37.13%
6 months-14.21%
Current year-12.68%
More quotes
1 week
26.51
Extreme 26.51
28.37
1 month
22.89
Extreme 22.89
29.97
Current year
17.58
Extreme 17.58
32.40
1 year
17.58
Extreme 17.58
41.49
3 years
17.58
Extreme 17.58
130.50
5 years
17.58
Extreme 17.58
130.50
10 years
17.58
Extreme 17.58
130.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 12-02-29
Director of Finance/CFO 48 16-08-31
Chairman 35 12-06-30
Members of the board TitleAgeSince
Director/Board Member 62 20-05-27
Director/Board Member 67 20-05-27
Chief Executive Officer 45 12-02-29
More insiders
Date Price Change Volume
24-04-30 27.96 +1.05% 2,285,804
24-04-29 27.67 +4.34% 3,323,469
24-04-26 26.52 +2.83% 2,452,196

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.96 CNY
Average target price
35.72 CNY
Spread / Average Target
+27.75%
Consensus
  1. Stock Market
  2. Equities
  3. 688105 Stock